Santaris Pharma Gains Another Collaborator in BMS
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 23 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1926 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol-Myers Squibb is the latest pharmaceutical company to access Santaris Pharma’s locked nucleic acid (LNA) technology for the discovery and development of RNA-targeted therapies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS